PathAI to present AI-powered research insights at the European Association for the Study of the Liver Congress 2024

Company Announces Presentations of Three Posters Highlighting Their Latest Research, Supported by the Recently Expanded Product Offering, Liver Explore

BOSTON — June 3, 2024 — PathAI, a leading provider of AI-powered pathology, is proud to present three posters at the European Association for the Study of the Liver’s International Liver Congress 2024 (EASL) in Milan, Italy from June 5 to 8, 2024. During EASL, PathAI will also formally reintroduce their innovative AI product, Liver Explore (previously known as NASH Explore), to further the understanding of liver diseases, including and beyond MASH.

PathAI will be presenting two posters that highlight the power of Liver Explore:

• PathAI revealed that Liver Explore measurements of fibrosis demonstrate strong association with non-invasive tests (NITs), progression to liver-related events (LRE), and discriminatory potential for distinguishing between cohorts consisting of different fibrosis stages cohorts. (Poster THU-261) Poster Session: June 6, 8:30AM - 6:00PM CEST
• PathAI utilized Liver Explore to exhaustively characterize the fibrosis subtypes present as fibrosis stages (both ordinal CRN stages and AIM-MASH+ predicted continuous stages) increase. These results provide key information on the granular changes in fibrosis composition that accompany MASH progression. (Poster THU-216) Poster Session: June 6, 8:30AM - 6:00PM CEST

Additionally, PathAI will present one poster demonstrating the accuracy of the AIM-MASH AI Assist (previously AIM-NASH) tool for MASH CRN scoring, as well as for the assessment of relevant MASH trial enrollment and endpoint criteria.

• The data in this study shows that AIM-MASH AI Assist may help to standardize histologic scoring for MASH clinical trials by reducing variability in MASH scoring and allowing for a more reliable assessment of therapeutics under development. (Poster #TOP-289) Poster Session: June 5, 8:30AM - 6:00PM CEST

In addition, PathAI is excited to unveil a new identity for NASH Explore, their AI-derived panel of histopathology features for spatial characterization of MASH biopsy tissue microarchitecture at the cellular-level from H&E whole-slide images. Responding to partner desire for similar insights into diseases beyond MASH, including Alcoholic Steatohepatitis (ASH) and Primary Sclerosing Cholangitis (PSC), the newly named Liver Explore¹ will help unlock insights to propel precision drug development in ways previously unavailable.

Liver Explore provides quantitative descriptions of liver microarchitecture to uncover insights into drug MOA and beyond. Liver Explore expands on PathAI’s expertise in the MASH field and includes over 1,000 histopathology features capturing liver cell, tissue, lobular zones and fibrosis subtypes for analysis. Liver Explore was designed to be incorporated seamlessly into existing workflows, allowing for rapid and scalable interrogation into patterns of fibrosis that reflect true disease progression and regression. Liver Explore was developed to not only infer the presence of fibrosis in whole slide images of H&E-stained tissue sections, but also 1) categorize fibrosis into clinically relevant subtypes, and 2) quantify the presence of these fibrosis subtypes in liver lobular zones.

For more information, visit booth O-5 at EASL for live demos and to meet the PathAI team. Contact us at [email protected] for additional information or visit www.pathai.com/mash.

Footnotes

1 Liver Explore is for research use only. Not for use in diagnostic procedures.

About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com.